|Bid||183.02 x 1400|
|Ask||183.84 x 1000|
|Day's Range||181.50 - 187.69|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||224.17|
Many who want to get marijuana legally turn to Weedmaps ($WEEDMAPS), a user-generated-content website "where businesses and consumers can search and discover cannabis products" among other services it offers. In layman's terms, it is the Google Maps of weed. It's the legitimate, web version of asking a friend who knows a guy who knows a guy's cousin who might sell marijuana. For the sake of breaking down the weed industry in our own backyard, let's take a deeper dive into how many places one could get marijuana by doing a quick search on this website.
Comparing GW Pharmaceuticals’ Returns to PeersGW PharmaceuticalsGW Pharmaceuticals (GWHP) is primarily into the development of cannabis-derived prescription medicines. Liquid cannabidiol (or CBD) is the leading product in the company’s
GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received positive results.The combination of the earnings beat and forward movement of Epidiolex, provide catalysts that should continue to drive GWPH stock price higher.The CatalystsRevenue in the latest reporting period ended March 31, 2019 came in at $39.2 million, far above the $3 million in revenue generated in the same reporting period of 2018, beating estimates by $23.33 million.Earnings for the quarter improved to a loss of $50.1 million, against the loss of $69.5 million year-over-year. Earnings per share was $-0.14, beating estimates by $0.07.Cash and cash equivalents fell from $591.5 million at the end of calendar year 2018, to $521.7 million at the end of the quarter.The second catalyst was the report of the company reaching another "primary efficacy measure with both EPIDIOLEX doses as compared to placebo." That was the "consecutive positive Phase 3 pivotal trial for EPIDIOLEX." The company is expected to file an sNDA in the fourth quarter of 2019.Net sales of Epidiolex in the quarter was $33.5 million, accounting for the majority of the revenue.Things to Consider for Current ShareholdersThere are a couple of important things to take into consideration with existing shareholders, including its share price and whether or not it can break out from its recent new highs.With its improvement with revenue and earnings, and its consistent positive news about Epidiolex, it would take a significant negative catalyst to reverse the sentiment in regard to the company, which suggests it may still have a lot of upward trajectory left.For that reason, unless shareholders want to take some profits off the table, it appears to be a low-risk play to maintain a position because the share price has a lot more room to run.Thoughts on Investors Looking to Take a Position in GWPHInvestors wanting to move quickly in and out of the stock would do better to wait to see if it drops below the recent breakout line before taking a position. Being a volatile stock, it would be best to wait for it to pull back and play the bounce if it comes.Spending is of particular concern, as the company projected operating expenses in a range of $395 million to $425 million for full-year 2019. It's almost certain that sales won't be able to cover those costs.The good news is at the end of the quarter the company had $521.7 million in cash, along with an additional $105 million it received from the sale of a review voucher in April.Even with rapidly growing revenue, increasing insurance coverage of the treatment, and its success in clinical trials, the company will continue to struggle to generate a profit in the near term. For that reason, investors wanting a stronger risk/reward metric, will probably stay away until the company shows it can generate a profit.One significant event that could be a powerful catalyst for GW Pharmaceuticals is if an European advisory committee gives approval this quarter for Epidiolex. If that's how it's plays out, patients with LGS and Dravet syndrome will have access to the treatment, providing a major boost in sales, and a quicker path to profitability; there already is pricing and reimbursement in place in key European markets Germany and France.With all the expansion and additional costs, management believes the $521.7 million in cash and cash equivalents should be enough to cover the next 12 months.ConclusionGW Pharmaceuticals continues to prove it has a lot going for it, with it continuing to grow Epidiolex revenue, expand its footprint, and lowering costs while it's doing so.Both revenue, earnings and Epidiolex are all moving in the right direction together, and that provides a bullish scenario that should continue to support and push up the share price of the company, even though I suspect there will be a correction in the near future after its share price has almost doubled so far in 2019.For long-term holders, it will be a chance to add more to your position and lower your cost basis.As the company stands today, I think the long-term opportunity outweighs the short-term, because of the price support and accompanying contracting price range the company will trade in on a daily basis when it's volatile.If you believe in GW and are in it for the long haul, there's really not much to do but hold on to your shares and ride the upward wave. I would be patient if you want to add to your position, waiting for the inevitable pullback.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks * GW Pharmaceuticals (GWPH): A “Blue Chip” Cannabis Stock to Watch More recent articles from Smarter Analyst: * Love or Hate Aurora Cannabis (ACB) Stock, That’s Where the Money Is * Micron's (MU) Tech Roadmap Highlights Flattening Cost Curve, Says Analyst; Reiterates Neutral on the Stock * Time to Cash Out on Cannabis Stock Canopy Growth (CGC) * Trade Tensions Bring Micron (MU) Stock Down, But Cascend Remains Bullish
Does GW Pharmaceuticals PLC (GWPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
The cannabis market has the potential to be extremely lucrative for investors. For example Quebec-based cannabis grower Hexo Corp (HEXO) is now up 107% year-to-date. But you have to know which stocks to look out for- as not all cannabis stocks are primed for success. And one way to go about this is to find the stocks with the most bullish outlook according to the Street. Here we delve deeper into three such stocks, that all show a ‘Strong Buy’ consensus from top-performing analysts. These are the analysts who consistently outperform the market, so their advice is worth following. Let’s take a closer look now: GW Pharmaceuticals (NASDAQ:GWPH)There’s no denying that this cannabis biotech is on a roll. GWPH develops and commercializes plant based cannabinoid therapies. Its key drug Epidiolex is marketed for the treatment of seizures associated with LennoxGastaut syndrome and Dravet syndrome. And with a strong Epidiolex launch and uptake trends so far, management is already demonstrating impressive execution in a very competitive market.Most notably, GWPH has just reported Epidiolex revenues of $33.5M, more than double some estimates, thanks to uptake among new patients and the transition from expanded access and open-label extension programs (EAP/OLE) to commercial product. Even more importantly, the company also shared positive topline results from a Phase 3 study of Epidiolex in patients with seizures associated with tuberous sclerosis complex (TSC).Such strong earnings prompted Oppenheimer’s Esther Rajavelu to upgrade GWPH from ‘Hold’ to ‘Buy.’ Following this upgrade, GWPH has now received 10 back-to-back buy ratings from analysts covering the stock in the last three months. That’s with a $220 price target, indicating upside potential of over 23%. “GWPH is uniquely positioned as the only phytocannabinoid company with an FDA-approved, marketed therapeutic agent (Epidiolex), and a validated platform it can leverage broadly” Rajavelu told investors.She continues: “Our Outperform thesis is based on our view that the potential for Epidiolex use in multiple seizure types including those associated with tuberous sclerosis complex, as well as other pipeline opportunities, are not fully reflected in the stock at current levels.” Following the latest trial results, the analyst updated the the probability of approval of the sNDA (supplemental new drug application) for TSC to 87% from 41% previously, and expects the filing to be submitted in Q4. Interestingly, UK-based GWPH also boasts a ‘perfect’ Smart Score of 10/10. This new rating system compiles 8 different data sets- from analyst ratings to the latest insider activity- to rank stocks out of ten. Here GWPH scores highly not just with the analysts but also with both bloggers and hedge funds. That's alongside Very Positive news sentiment, and positive momentum with shares up 22% over the last year. See what other Top Analysts are saying about GWPH. Aphria Inc (NYSE:APHA)GWPH isn’t the only cannabis stock out there with strikingly positive Street sentiment. Canadian cannabis giant Aphria has also received only buy ratings from analysts in the last three months. That’s despite a horrific 2018 featuring a takeover attempt and short seller allegations of devious insider dealings. But with a board investigation complete and a new CEO at the helm (Irwin Simon) the tide is now turning. And so it’s worth taking a closer look at Aphria now while the stock is still trading at discounted levels. “We believe Aphria is on the cusp of a major production ramp along with significant economies of scale for production and SG&A costs. Given our increased CY2020e Adj. EBITDA estimate, we are raising our 12-month target price to $24.75 per share (from $22.75)” cheers Clarus analyst Noel Atkinson. From current levels this indicates huge upside potential of 136%.He blames limited capacity and production bottlenecks for the recent disappointing earnings results, but sees brighter days ahead. “If management can guide the pending production ramp effectively, we believe there is the potential for a very substantial re-rating of the stock price from current levels. We reiterate our Buy rating” the analyst concluded. Bear in mind, APHA shares have already exploded by 550% in the last three years. So what kind of growth can we expect? Well, management recently provided targets of $500MM of Canadian cannabis revenue (annual run-rate) by the end of CY2019 and $1 billion by the end of CY2020. That expansion now looks closer than ever due to the Health Canada licensing for the crucial Part IV/V expansion (80,000 kg/year) at Aphria One that was received right after quarter-end on March 4- which means Aphria One’s full capacity should reach consumers as early as this summer. Plus the new Aphria Diamond facility should come on line soon. “We continue to believe that Aphria has developed one of the most automated and highly sophisticated cultivation facilities in the world at Aphria One, and we expect Aphria Diamond (140,000 kg/year) to have similar capabilities once it is licensed” writes Atkinson. The analyst adds: “We understand Aphria Diamond is essentially completed and awaiting Health Canada inspection to begin cultivation.”From a Smart Score perspective however Aphria receives a more muted score of six. Even though the stock scores highly with both analysts and bloggers, and has a Very Bullish news sentiment for the past week, its sentiment from investors is Positive (vs Very Positive for GWPH) with both the technicals and fundamentals in the red. See what other Top Analysts are saying about APHA. Canopy Growth Corp (NYSE:CGC) (TSE:WEED)This piece would not be complete without our third stock, Canopy Growth Corp. In just one year shares in CGC, the world’s largest cannabis stock by market cap, have doubled. Now if you look at all the analyst ratings received by CGC over the last three months, the stock shows a cautiously optimistic Moderate Buy consensus. But if we include only those ratings published by best-performing analysts, the consensus shifts to Strong Buy. In fact, CGC has received five consecutive buy ratings from top-performing analysts in the last three months. And if we look at the Canadian ticker TSE:WEED, that’s with an average analyst price target of C$83, for upside potential of just over 30%. What’s more CGC’s most recent rating comes from Martin Landry of GMP FirstEnergy. This is one of the Top 20 analysts ranked by TipRanks out of over 5,190 analysts thanks to his savvy stock picking skills. He reiterated his buy rating on CGC with a C$72 price target- having upgraded the stock from Hold to Buy in April following the news that CGC has acquired the rights to snap up organic cannabis company Acreage Holdings. As far as the Street is concerned, this deal provides CGC with a straightforward “path for the U.S. cannabis market.” Landry himself writes “This transaction should boost Acreage’s ability to consolidate the U.S. market.” That means “when Canopy officially takes ownership of Acreage, it could be much larger than currently.”The analyst has now returned from a very insightful tour of the company’s activities in British Columbia (BC), including both the company’s Aldergrove and Delta facilities.“The BC greenhouses appear to be running smoothly across all areas of production, trimming and drying,” the analyst commented- silencing rumors of dead cannabis plants that have plagued CGC since a video back in 2018 purported to show total crop failure at Aldergrove.According to Landry, “The facilities are ramping up production with only 400k sq. ft. of greenhouse currently unlicensed, the application for which has been submitted. With a number of harvests already under the belt, the ramp up focus is on increasing yields and shortening cycle time. WEED expects it can achieve an equivalent of over four harvests per year. Canopy has trimming and drying capacity to handle the full production of the BC Tweed facilities.” He believes Canopy’s BC facilities could eventually produce 300 tonnes of cannabis annually, with a production cost of $0.50/ per gram.With the stock showing such strong momentum, CGC also sports a 10/10 from TipRanks’ Smart Score, despite Very Negative sentiment from investors. See what other Top Analysts are saying about CGC. Enjoy Research Reports on the Stocks in this Article:Aphria Inc (APHA) Research ReportCanopy Growth Corp (CGC) Research ReportGW Pharmaceuticals (GWPH) Research Report
The cannabis world had an unlikely protagonist: magic mushrooms . After a popular vote, the city of Denver, Colorado, known as a legal cannabis trailblazer, approved a ballot measure to decriminalize psychedelic ...
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Scotts Miracle-Gro, Ambev, International Game Technology and Ubisoft Entertainment
LONDON, May 09, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science,.
GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) BioSig Technologies ...
This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.
GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH ) opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats. Here’s what analysts are ...
GW Pharma reported Monday after the close with positive topline results from a Phase 3 study of Epidiolex in the treatment of seizures associated with tuberculosis sclerosis complex, or TSC. TSC is a rare genetic condition that causes tumors in different body organs, most often in the brain, skin, heart, eyes, kidneys and lungs, causing a variety of health problems.
Sunday night's equity futures trading foretold an ominous Monday open, and it was red indeed. But then the surprise was that the indices recovered almost all their losses by day's end. Even among the mid-morning selloff there were a few good stories to tell. As the indices were still falling, I saw favorable price action from stocks like GW Pharmaceuticals (NASDAQ:GWPH) stock and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). So I jumped long on the GWPH trade because of its technical patterns in the stocks charts. And therein lies today's opportunity.I had noticed that GWPH stock had hit my upside target from the breakout that happened at $154 per share on their last earnings report. But there was now the setup going into a new breakout.InvestorPlace - Stock Market News, Stock Advice & Trading TipsLast night, GWPH reported earnings, and the investors are loving it. The marijuana stock is up almost 9% on the headline. My thesis was that there is conviction in the stock, enough to perhaps trigger another leg higher. If the bulls can maintain the breakout from the all-time high, they should target $235 per share -- or higher! Numbers for GWPH StockThe earnings were good, as management beat both the top and bottom lines. This will embolden analysts to continue to support the stock.But more exciting was that they also announced positive results from an important phase-3 trial on their Epidiolex oral medicine for patients who suffer from some types of epilepsy. * 7 Strong Buy Stocks That Tick All the Boxes This double positive headline should have legs, meaning the bears will need specific reasons to fade it. True there is the potential of a negative market wide headline from the White House and both biotech stocks and marijuana stocks can be a choppy bunch, but the selling effect on GWPH stock should be temporary.If you're long the stock, then the earnings report and the happy news from the phase 3 trials are reasons enough to stay long it. The next target should be $30 higher. But starting new positions now would require having a lot of faith in the overall market conditions and the immediate future of GW Pharma.This is not the same as saying that I don't see good things for GWPH. I am merely noting that this is not an obvious spot to go long a stock. It is, after all, at all time highs so there is always room to drop. But this also depends on the investor time frame.If my intention is to hold the stock for a long time then I shouldn't try to time the entry. Chasing a surgical entry point in the long term is futile. But for those who prefer to trade GWPH shorter term then I'd wait for a retest of the breakout line that we crossed this morning. Click to Enlarge Fundamentally, this is not a cheap stock so bulls need to have great intestinal fortitude to own it. It is a momentum stock, so it moves fast in either direction. But with high risk comes high rewards.GWPH came into the earnings report up almost 90% year-to-date. It's up almost 170% in five years. This is more than triple the performance of the S&P 500. So it does reward those who risk their capital on its froth.Depending on your perspective, there is the added benefit (or curse) of GWPH being bundled in with marijuana stocks. So for as long as that thesis is running wild then GWPH will trade along with them in stages.In short, this week is starting very bullish for GW Pharmaceutical stock. Management is delivering on promises so the stock should also continue to deliver profit to its holders. Up remains the thesis on it for the mid and long term.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits Compare Brokers The post GW Pharmaceuticals Stock Could Aim for $235 -- Or Higher! appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 6) Axsome Therapeutics Inc (NASDAQ: AXSM ) (FDA agreed to ...
GW Pharmaceuticals PLC shares soared 9% in premarket trade Tuesday, after Oppenheimer upgraded the stock to outperform from perform, after the company reported better-than-expected earnings along with positive results in a late-stage trial of its Epidiolex treatment. Epidilolex is the first cannabis-based drug to win approval from the U.S. Food and Drug Administration as a treatment for severe forms of childhood epilepsy. The drug is now being tested as a treatment for patients with seizures associated with tuberous sclerosis complex, or TSC. "While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA for TSC to 87% from 41% (filing expected in 4Q), and move to an Outperform rating and a price target of $234 (vs. $162)," Oppenheimer analyst Esther Rajavelu wrote in a note to clients. "We also like management's efforts to broaden the pipeline with open label studies of CBDV for autism spectrum disorder and Rett syndrome which may contribute to a diversified portfolio." Stifel analysts led by Paul Matteis raised their stock price target to $227 from $191 and said dinner with GW management after the earnings report "reaffirms our view that the Epidiolex launch to date, considering all of the variables that have led the product to beat consensus, is going about as well as one could've hoped." Matteis is also expecting the drug to be approved for TSC in 2019. The analyst raised his revenue forecast for Epidiolex for the second quarter to $49 million from $26 million. GW Pharma shares have gained 85% in the last 12 months, while the S&P 500 has gained 10%.